【摘要】：目的：系統(tǒng)評價應(yīng)用抗真菌藥物聯(lián)合乳酸桿菌活菌制劑治療外陰陰道假絲酵母菌病(vulvovaginal candidiasis, WC)的療效和安全性。 方法：檢索PubMed、Embase、the Cochrane Central Register of Trial、 CBMdisc、CNKI、VIP和萬方等數(shù)據(jù)庫,收集使用抗真菌藥物聯(lián)合乳酸桿菌活菌制劑治療VVC的臨床隨機對照試驗(randomized controlled trials, RCTs),檢索時間截止至2014年2月。主要研究指標為：治愈率、復(fù)發(fā)率,次要研究指標為：癥狀緩解率、陰道pH值改善率、不良反應(yīng)。所有數(shù)據(jù)處理應(yīng)用ReviewManager5.2進行meta分析。 結(jié)果：共納入8篇RCT,包含1102例患有VVC的育齡期非孕女性(其中558例患者接受抗真菌聯(lián)合乳酸桿菌活菌制劑治療,544例患者接受抗真菌藥物聯(lián)合安慰劑或單一抗真菌藥物治療)。Meta分析結(jié)果顯示：抗真菌藥物聯(lián)合乳酸桿菌活菌制劑明顯提高治愈率(OR=3.40,95%CI:1.83～6.29,P=0.0001),降低復(fù)發(fā)率(OR=0.17,95%CI:0.09～0.33, P0.00001),提高癥狀緩解率(OR=3.80,95%CI:1.47～9.82, P=0.006),陰道pH值改善率(OR=1.42,95%CI:0.31～6.62, P=0.65)無顯著差異,不良反應(yīng)無統(tǒng)計學(xué)差異。 結(jié)論：抗真菌藥物聯(lián)合乳酸桿菌活菌制劑相較單一抗真菌藥物在治療VVC的治愈率、癥狀緩解率、降低復(fù)發(fā)率等方面有更優(yōu)的療效,且安全可行,可考慮作為臨床有效的輔助治療策略。
[Abstract]:Objective: to evaluate the efficacy and safety of antifungal drugs combined with active Lactobacillus preparation in the treatment of vulvovaginal candidiasis (vulvovaginal candidiasis, WC). Methods: the databases of PubMed,Embase,the Cochrane Central Register of Trial, CBMdisc,CNKI,VIP and Wanfang were searched, and the searching time of (randomized controlled trials, RCTs), in clinical randomized controlled trial (randomized controlled trials, RCTs),) with antifungal drugs combined with active Lactobacillus preparation for treatment of VVC was collected until February 2014. The main indicators were: cure rate, recurrence rate, secondary study index: symptom relief rate, vaginal pH improvement rate, adverse reaction. All data processing is analyzed by meta using ReviewManager5.2. Results: a total of 1102 non-pregnant women with VVC were included in 8 RCT, articles (558 of them received antifungal therapy combined with live Lactobacilli preparation and 544 received antifungal drugs combined with placebo or single antifungal agents). The results of). Meta analysis showed that antifungal drugs combined with active Lactobacillus preparations significantly increased the cure rate (OR=3.40,95%CI:1.83~6.29,P=0.0001), decreased the recurrence rate (OR=0.17,95%CI:0.09~0.33, P0.00001), improved the remission rate of symptoms (OR=3.80,95%CI:1.47~9.82, P0. 006), and improved the pH value of vagina (OR=1.42,95%CI:0.31~6.62, P0. 65). There was no statistical difference in adverse reactions. Conclusion: the antifungal drugs combined with the active Lactobacillus preparations have better curative effect than the single antifungal drugs in the treatment of VVC in the aspects of cure rate, symptom relief rate and reduction of recurrence rate, and are safe and feasible. It can be considered as an effective adjuvant therapy strategy.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R711.31

【參考文獻】

相關(guān)期刊論文 前2條

1 夏艷;金志軍;;外陰陰道假絲酵母菌病治療的研究進展[J];國際婦產(chǎn)科學(xué)雜志;2011年02期

2 吳文湘;劉朝暉;;外陰陰道假絲酵母菌病的診治進展[J];國際婦產(chǎn)科學(xué)雜志;2011年06期

，

本文編號：2280188